An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma

The investigators plan to develop a deep learning-based automatic interpretation model for Claudin18.2(CLDN18.2) using the institution's and multiple other centers' extensive pathological resources of digestive system adenocarcinomas. This study will not only strictly follow the latest domestic expert consensus and standards, but also aims to address current pain points in manual interpretation. It seeks to provide technical support for standardizing, objectifying, and streamlining CLDN18.2 testing, thereby advancing the application of precision medicine in the diagnosis and treatment of digestive system diseases. The project has clear clinical necessity and broad application prospects.

NCT Number	NCT07274579
Lead Sponsor	Nanfang Hospital, Southern Medical University Collaborators: Qianfoshan Hospital
Conditions	Digestive Oncology
Enrollment	2,000 participants
Start Date	2025-10-01
Primary Completion	2028-07 (estimated)
Study Completion	2028-08 (estimated)
Updated on ClinicalTrials.gov	2026-02-10